Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.55
Bid: 2.50
Ask: 2.60
Change: -0.325 (-11.30%)
Spread: 0.10 (4.00%)
Open: 2.875
High: 2.875
Low: 2.55
Prev. Close: 2.875
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Eco Animal expects earnings below consensus

Tue, 15th Mar 2022 10:53

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

ValiRx PLC, up 14% at 23.61 pence, 12-month range 17.26p-63p. The cancer and women's health treatment developer says it is assessing options to acquire capabilities and infrastructure to create a "more efficient and effective" translational drug development service. Says revenue generated from providing pre-clinical development services would enable continued investment in advanced testing and analysis technology and support the progression of ValiRx in-house pipeline projects.

----------

Tlou Energy Ltd, up 13% at 2.14p, 12-month change 1.57p-4.9p. The power company says contract for the construction of the transmission line to connect the Lesedi power project to Botswana's electricity grid has been signed. Botswana-based Zismo Engineering Pty Ltd has been engaged to construct the line, and expects to mobilise plant and equipment on site in the coming weeks.

----------

AIM - LOSERS

----------

Mobile Streams PLC, down 20% at 0.3155p, 12-month range 0.2p-0.71p. The mobile content provider raises GBP1.2 million in placing priced at 0.30p per share. Funds to support company's growth and to create a new joint venture partnership with Gfinity PLC for Mobilegaming.com. "The company is working to agree the terms of the joint venture and expects to announce the conclusion of the agreement shortly," it says. Gfinity shares rise 11%.

----------

Eco Animal Health Group PLC, down 18% at 123.49p, 12-month change 116.55p-405p. The pet and livestock pharmaceuticals firm expects earnings before interest, tax, depreciation and amortisation for year ending March 31 to be 15% to 20% below consensus expectations amid investment. "The pork commodity price in China continues to be volatile but we are pleased with recent trading and our expectation of meeting revenue consensus is an important indicator of a return to more stable trading conditions," says Chief Executive Marc Loomes.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
10 Jun 2014 10:00

ValiRx Submits Application For VAL201 Cancer Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer therapeutic candidate.

Read more
10 Jun 2014 09:45

Tuesday broker round-up UPDATE

ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 680p and downgrades from buy to add. BAE Systems: Investec downgrades from add to hold with a target price of 430p. BG Group: Exane downgrades to neu

Read more
15 May 2014 13:31

ValiRx Sees Progress On Cancer Drug Development From Joint Venture

LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase II trials since the formation of its joint venture with Tangent Reprofiling Ltd, ValiSeek. The joint venture was formed a month ago to progre

Read more
1 May 2014 10:15

ValiRx Granted Patent For Cancer Screening Biomarker In Japan

LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012. As a result, ValiRx now has patent protection on this biomarker i

Read more
8 Apr 2014 11:05

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development

LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tangent's VAL401 potential cancer drug through its remaining preclinical development and towards Phase II trials. ValirX said it has acquired a 6

Read more
1 Apr 2014 09:22

ValiRx Anti-Cancer Compound To Undergo Further Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study. ValiRx said it had accepted the advice of the tea

Read more
19 Mar 2014 12:10

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme

LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment in the clinical trial programme for its anti-cancer therapeutic VAL201. The company posted a pretax loss of GBP2.9 million, widened from GBP2

Read more
20 Feb 2014 11:10

ValiRx Biomarket Receives European Patent Approval

LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received patent approval from the European Patent Office. In a statement, ValiRx said the latest approval means it has biomarker patent protection in

Read more
31 Jan 2014 13:03

ValiRx Sells Shares In VolitionRx For USD601,578

LONDON (Alliance News) - ValirRx PLC Friday said it has sold its shareholding in VolitionRx to an unnamed firm for USD601,578 and will use the proceeds for the continuing clinical development of its anti-cancer therapeutics VAL101 and VAL201. The life science company had 510,811 shares in c

Read more
27 Dec 2013 08:27

ValiRx Raises GBP2.9 Million In Placing To Fund Oncology Work

Read more
28 Nov 2013 12:27

CORRECT: AIM IN BRIEF: Herstal Emerges As Favourite To Acquire Manroy

Read more
28 Nov 2013 08:22

AIM IN BRIEF: Beretta Emerges As Favourite To Acquire Manroy

Read more
15 Nov 2013 12:39

CORRECT: ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more
15 Nov 2013 12:37

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

Read more
15 Nov 2013 10:28

ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.